About us
It is developed for the treatment of cancer or cancer-related complications
And a biotechnology enterprise based on bispecific antibody therapy for senile eye diseases
Company introduction
Wuhan Youzhiyou Biopharmaceutical Co., LTD

Wuhan Youziyou Biopharmaceutical Co., Ltd. is a biotechnology company dedicated to developing bisspecific antibody (BsAb) based therapies for the treatment of cancer-related complications, cancer and senile eye diseases to address medical needs in the field of oncology and geriatric ophthalmology。The company's mission is to develop innovative medicines to safeguard human health。


Since its establishment in 2010, Youzhiyou Biology has adhered to independent innovation, layout and deep cultivation in the field of bisspecific antibodies, and developed four innovation platforms, including self-developed YBODY®Platform, Check-BODY platform and Nano-YBODYTMPlatform and UVAX developed in cooperation with Wuhan Institute of Virology®Platform, the company has designed and developed seven clinical stage drug candidate pipelines。

  • 4
    Innovation platform
  • 80 %
    R&d personnel
  • 78
    Patents (33 granted, 45 under review)
Leadership team
president&General MANAGER
Dr. Zhou Pengfei
Dr. Zhou Pengfeipresident&General MANAGER

Dr. Zhou Pengfei, co-founder, Chairman and Chief Executive Officer, is responsible for the overall strategic planning of the Group and the management of the supervisory and regulatory business。Dr. Zhou received his Bachelor's degree in Pediatrics and his Master's degree in Pediatric Surgery (Oncology) from Tongji Medical University in June 1989 and June 1994, respectively。He received his Doctor of Medicine degree from McMaster University in November 2005。

Dr. Zhou has over 33 years of experience in the healthcare and pharmaceutical industries, including working for Schering-Plough Corporation, Sino-US Crown Biology and other leading companies in the field of tumor biology and tumor immunotherapy。

Dr. Zhou is currently a visiting professor of Tongji Medical College of Huazhong University of Science and Technology and a visiting professor of Central South University。

Vice President, Production Center
Dr. Yang Bin
Dr. Yang BinVice President, Production Center

Dr. Yang Bin, currently Vice President of the Production Center, is responsible for implementing the Group's technology development and product manufacturing strategies and objectives。Dr. Yang received a Bachelor's degree in Pharmacy from Wuhan University and a doctorate degree in biomedicine from Jinan University。

Prior to joining Youzhiyou Biology, Dr. Yang served as Director of monoclonal antibody Department and deputy Director of Research Institute in Shenzhen Dongguang Industrial Development Co., LTD and its subsidiary (Dongguang Group)。

Supervisor, Senior Director of R&D Center
张敬
张敬Supervisor, Senior Director of R&D Center

Jing Zhang has served as our Supervisor since February 2018。Mr. Zhang joined the Group in January 2011 and has successively served as Senior Research Assistant of the Company's R&D Center, Senior Manager of the Company's Cell Line Development Department and Director of the Company's R&D Center。In May 2023, he was promoted to Senior Director of the Company's Research and Development Center, where he is responsible for overseeing operational and financial activities and leading the research and development Center。

Prior to joining the Group, Mr. Zhang served as a research assistant at the Institute of Biophysics, Chinese Academy of Sciences from August 2008 to December 2010。He has been a supervisor of Wuhan Huiyou Juyou Enterprise Management Co., LTD., since June 2022。

Mr. Zhang received a bachelor's degree in biotechnology from the School of Life Sciences of Wuhan University and a Master's degree in Biochemistry and Molecular Biology from the Graduate School of the Chinese Academy of Sciences。

Senior clinical director
Huang Shaoyi
Huang ShaoyiSenior clinical director

Dr. Shaoyi Huang, currently Senior Director of Clinical Division, is responsible for academic support of the Company's clinical programs and the development of policies and management processes related to clinical research。

Dr. Huang has rich experience in clinical research and product development. From March 2014 to July 2020, Dr. Huang served as the Deputy Director of the Oncology Department of Wuhan Youzhiyou Medical Technology Co., LTD., responsible for research and development and clinical work。

Dr. Huang received his Bachelor's degree in Biotechnology and Master's degree in Microbiology from Wuhan University in June 2001 and December 2004 respectively。He received his Ph.D. in cancer biology from the University of Texas Health Science Center at Houston and the University of Texas M.D. Anderson Cancer Center in August 2013。

  • Dr. Zhou Pengfei, co-founder, Chairman and Chief Executive Officer, is responsible for the overall strategic planning of the Group and the management of the supervisory and regulatory business。Dr. Zhou received his Bachelor's degree in Pediatrics and his Master's degree in Pediatric Surgery (Oncology) from Tongji Medical University in June 1989 and June 1994, respectively。He received his Doctor of Medicine degree from McMaster University in November 2005。

    Dr. Zhou has over 33 years of experience in the healthcare and pharmaceutical industries, including working for Schering-Plough Corporation, Sino-US Crown Biology and other leading companies in the field of tumor biology and tumor immunotherapy。

    Dr. Zhou is currently a visiting professor of Tongji Medical College of Huazhong University of Science and Technology and a visiting professor of Central South University。

  • Dr. Yang Bin, currently Vice President of the Production Center, is responsible for implementing the Group's technology development and product manufacturing strategies and objectives。Dr. Yang received a Bachelor's degree in Pharmacy from Wuhan University and a doctorate degree in biomedicine from Jinan University。

    Prior to joining Youzhiyou Biology, Dr. Yang served as Director of monoclonal antibody Department and deputy Director of Research Institute in Shenzhen Dongguang Industrial Development Co., LTD and its subsidiary (Dongguang Group)。

  • Jing Zhang has served as our Supervisor since February 2018。Mr. Zhang joined the Group in January 2011 and has successively served as Senior Research Assistant of the Company's R&D Center, Senior Manager of the Company's Cell Line Development Department and Director of the Company's R&D Center。In May 2023, he was promoted to Senior Director of the Company's Research and Development Center, where he is responsible for overseeing operational and financial activities and leading the research and development Center。

    Prior to joining the Group, Mr. Zhang served as a research assistant at the Institute of Biophysics, Chinese Academy of Sciences from August 2008 to December 2010。He has been a supervisor of Wuhan Huiyou Juyou Enterprise Management Co., LTD., since June 2022。

    Mr. Zhang received a bachelor's degree in biotechnology from the School of Life Sciences of Wuhan University and a Master's degree in Biochemistry and Molecular Biology from the Graduate School of the Chinese Academy of Sciences。

  • Dr. Shaoyi Huang, currently Senior Director of Clinical Division, is responsible for academic support of the Company's clinical programs and the development of policies and management processes related to clinical research。

    Dr. Huang has rich experience in clinical research and product development. From March 2014 to July 2020, Dr. Huang served as the Deputy Director of the Oncology Department of Wuhan Youzhiyou Medical Technology Co., LTD., responsible for research and development and clinical work。

    Dr. Huang received his Bachelor's degree in Biotechnology and Master's degree in Microbiology from Wuhan University in June 2001 and December 2004 respectively。He received his Ph.D. in cancer biology from the University of Texas Health Science Center at Houston and the University of Texas M.D. Anderson Cancer Center in August 2013。

Development course
Course of 2010
7月

The predecessor of the company, Wuhan Youzhiyou Biopharmaceutical Co., Ltd. was established 

BsAb platform started development

Course of 2012
5月
Establish GMP compliance quality system
11月

Development of M802 started

Filed a PCT patent application for "bispecific antibody" to protect YBODY®平台

Course of 2013
7月
Development of M701 started
12月
The molecular structure of M802 and M701 was determined
Course of 2014
6月
"New tumor therapeutic bisspecific antibody drug development project" was selected as a major scientific and technological project of "Major New Drug Creation" in the 12th Five-Year Plan
Course of 2015
9月
M701 was selected as a major scientific and technological project of "Major New Drug Creation" in the 12th Five-Year Plan
Course of 2016
4月
The M802 became the first BsAb in China to declare an IND
8月
Completed a Pre-A round of financing(1)The total amount of funds raised is about 50 million yuan
Course of 2017
2月

YBODY®The platform's patent protection in the United States has been expanded to 35 targets
The M701 became the second BsAb in China to file an IND

9月
The M802 clinical study in China has obtained IND approval from the State Food and Drug Administration, which is the first IND approval for the self-developed BsAb in China
Course of 2018
2月
M701 received the second IND approval for China's self-developed bisspecific antibody
3月

Establish the Check-BODY platform

4月
Completed Series A financing (1), raising a total of about RMB 157.Two million
12月

M802 China patent granted protection

Build the Nano-YBODY platform

YBODY®The platform's CD3 and HER2 dual-target antibody patents are granted protection in the United States

Course of 2019
7月
The PCT patent protection application for the Check-BODY technology platform was filed
8月
The M802 clinical trial application was approved by the US FDA IND
10月
M701 clinical trial application received FDA IND approval
2020 journey
2月
Create a UVAX®平台
8月
Y150 clinical trial application was approved by US FDA IND
Course for 2021
1月

Completed Series B financing(1)The total amount of funds raised is about RMB 168.Seven million

The rrMM clinical trial application for Y150 was approved by IND of China State Drug Administration

The Y101D clinical trial application has received IND approval from the US FDA for the treatment of solid tumors

2月
Completed Series B+ financing(1)The total amount of funds raised is about 20 million yuan
5月
The clinical trial of Y101D with metastatic or locally advanced solid tumors was approved by China's State Drug Administration (IND)
8月
Completed the B++ round of financing(1)The total amount of funds raised is about RMB 73.Five million
12月

Y2019 clinical trial application was approved by IND of China State Drug Administration

Initiating a Phase II MA trial of M701 monotherapy in combination with systemic therapy in patients with EPCAM-positive tumors in China

Journey to 2022
1月
The company was converted into a limited company, and the company name was changed to "Wuhan Youzhiyou Biopharmaceutical Co., LTD."
7月

The Phase Ib/II clinical trial of M701 in the treatment of MPE was approved by IND in China

Entered into an asset transfer agreement with Kang Zhewei Sheng for Y400

10月
Completed a Series C funding round(1)The total amount of funds raised is about 2 million yuan
12月

Obtained IND approval for Y101D in combination with gemcitabine and albumin-paclitaxel in a Phase Ib/II clinical trial in China as a first-line treatment for patients with pancreatic cancer

Obtained IND approval for Y101D in combination with bevacizumab in a Phase Ib/II clinical trial for HCC and other advanced solid tumors in China

Journey in 2023
4月

Y332 obtained IND approval from China State Drug Administration

Y400 obtained IND approval from China State Drug Administration

9月
Listed on the Main Board of the Hong Kong Stock Exchange, stock code: 2496
10月
Completed Y101D pancreatic cancer Phase II clinical trial enrollment
11月
Obtained the high-tech enterprise identification
12月
Completed the M701 MPE Phase Ib clinical trial
2010年
2012年
2013年
2014年
2015年
2016年
2017年
2018年
2019年
2020年
2021年
2022年
2023年
Contact information
  • Contact number:
    027-82668988
  • Company Email:
    info@yfchan.com
  • 邮编:
    430075
  • 地址:
    East Lake New Technology Development Zone, Wuhan City, Hubei Province
    Building C2-1, Optics Valley Bio City, 666 Gaoxin Avenue
  • 传真:
    027-68788819
  • Business cooperation Contact:
    BD@yfchan.com